Claims for Patent: 11,690,827

Summary for Patent: 11,690,827

Title:	Methods for treating ocular Demodex using lotilaner formulations
Abstract:	Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
Inventor(s):	Bobak Robert Azamian, Douglas Michael Ackermann, Shawn D. Hickok, Joseph G. Vehige
Assignee:	Tarsus Pharmaceuticals Inc
Application Number:	US17/873,548
Patent Claims:	1. A method for treating blepharitis caused by Demodex mites, comprising: topically administering directly to an ocular surface of one or more eyes of a human patient in need of treatment thereof an effective amount of an ophthalmic composition, wherein the ophthalmic composition comprises lotilaner and a pharmaceutically acceptable vehicle, and wherein the ophthalmic composition is in eye drop form. 2. The method of claim 1, where the lotilaner is the sole active ingredient of the ophthalmic composition. 3. The method of claim 1, wherein between about 0.15% and about 0.40% by weight of the lotilaner with respect to the total weight of the composition is administered. 4. The method of claim 1, wherein the ocular surface comprises at least one of the conjunctiva or cornea of the one or more eyes of the patient. 5. The method of claim 1, wherein the ophthalmic composition further comprises castor oil. 6. The method of claim 1, wherein topically administering further comprises topically administering between about 25 microliters and about 50 microliters of the ophthalmic composition to the patient at least one time daily for at least about 4 weeks. 7. The method of claim 6, wherein topically administering further comprises topically administering between about 25 microliters and about 50 microliters of the ophthalmic composition to the patient at least twice daily for at least about 6 weeks. 8. A method for treating eyelid margin redness caused by Demodex mites, comprising: topically administering directly to one or more of the eye, eyelids, or eyelashes of a human patient in need of treatment thereof an effective amount of an ophthalmic composition, wherein the ophthalmic composition comprises lotilaner and a pharmaceutically acceptable vehicle, and wherein the ophthalmic composition is in eye drop form. 9. The method of claim 8, wherein the patient's eyes are closed upon topically administering the ophthalmic composition, such that the ophthalmic composition contacts orifices of Meibomian glands of the patient and outside of eyelid margins of the patient. 10. The method of claim 8, wherein between about 0.15% and about 0.40% by weight of the lotilaner with respect to the total weight of the composition is administered. 11. The method of claim 8, wherein the ocular surface comprises at least one of the conjunctiva or cornea of the one or more eyes of the patient. 12. The method of claim 8, wherein the ophthalmic composition further comprises castor oil. 13. The method of claim 8, wherein topically administering further comprises topically administering between about 25 microliters and about 50 microliters of the ophthalmic composition to the patient at least one time daily for at least about 4 weeks. 14. The method of claim 13, wherein topically administering further comprises topically administering between about 25 microliters and about 50 microliters of the ophthalmic composition to the patient at least twice daily for at least about 6 weeks. 15. A method for eradicating Demodex mites, comprising: topically administering directly to an ocular surface of one or more eyes of a human patient in need of treatment thereof an effective amount of an ophthalmic composition, wherein the ophthalmic composition comprises lotilaner and a pharmaceutically acceptable vehicle, and wherein the ophthalmic composition is in eye drop form. 16. The method of claim 15, wherein between about 0.15% and about 0.40% by weight of the lotilaner with respect to the total weight of the composition is administered. 17. The method of claim 15, wherein the ocular surface comprises at least one of the conjunctiva or cornea of the one or more eyes of the patient. 18. The method of claim 15, wherein the ophthalmic composition further comprises castor oil. 19. The method of claim 15, wherein topically administering further comprises topically administering between about 25 microliters and about 50 microliters of the ophthalmic composition to the patient at least one time daily for at least about 4 weeks. 20. The method of claim 19, wherein topically administering further comprises topically administering between about 25 microliters and about 50 microliters of the ophthalmic composition to the patient twice daily for at least about 6 weeks.